Stock Update (NASDAQ:GILD): UK cost body backs pricey Gilead hepatitis pill for some patients

[Reuters - UK Focus] – * Gilead says decision potentially covers most patients * J&J cancer drug Zytiga rejected for use pre-chemotherapy LONDON, Aug 15 (Reuters) – Gilead Sciences (NasdaqGS: GILD – news) . . . → Read More: Stock Update (NASDAQ:GILD): UK cost body backs pricey Gilead hepatitis pill for some patients Similar Articles: Stock Update: Gilead Sciences Inc (NASDAQ:GILD) – England agrees funding for Gilead hepatitis C drug Gilead Sciences Inc. (NASDAQ:GILD) – Gilead to seek okay for combo hepatitis C pill in Q1 AbbVie Inc. (NYSE:ABBV) ~ AbbVie’s hepatitis C treatment helps 96 pct of patients in trial